#1 Clinical Trials Search in Europe

Atl001

ATL001 is an innovative personalized therapy currently being tested in clinical trials for patients with advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma. This treatment uses the patient’s own T cells, which are modified to target specific mutations found in their cancer cells. The trials aim to evaluate the safety and effectiveness of ATL001 when used alone or in combination with other immunotherapy drugs.

Table of Contents

What is ATL001?

ATL001 is an innovative personalized therapy being developed to treat advanced cancers[1][2]. It belongs to a category of treatments called Advanced Therapy Medicinal Products (ATMPs), specifically a type of cell therapy[1][2]. This means ATL001 uses living cells as part of the treatment.

How ATL001 Works

ATL001 is a type of therapy called neoantigen reactive T cells[1][2]. Here’s a simplified explanation of how it works:

  1. The treatment is personalized for each patient.
  2. It targets specific mutations (changes in DNA) that are found in all of a patient’s cancer cells[1][2].
  3. T cells (a type of immune cell) are taken from the patient’s body.
  4. These T cells are modified to recognize and attack the patient’s specific cancer mutations.
  5. The modified T cells (ATL001) are then given back to the patient to fight the cancer.

Target Conditions

ATL001 is being studied for two main types of advanced cancers:

  • Non-small cell lung cancer (NSCLC): This is a type of lung cancer that has spread to other parts of the body or has come back after previous treatment[1].
  • Metastatic or recurrent melanoma: This is a type of skin cancer that has spread to other parts of the body or has come back after previous treatment[2].

Clinical Trials

ATL001 is currently being tested in clinical trials. These trials are designed to:

  • Assess how safe ATL001 is for patients[1][2].
  • Determine how well patients tolerate the treatment[1][2].
  • Evaluate how effective ATL001 is at treating cancer[1][2].

The trials are testing ATL001 both as a standalone treatment and in combination with other cancer drugs called pembrolizumab (for lung cancer)[1] or nivolumab (for melanoma)[2].

Administration

ATL001 is given to patients through an intravenous infusion[1][2]. This means it’s delivered directly into the bloodstream through a vein. Before receiving ATL001, patients typically undergo a process called lymphodepletion, which helps prepare their body for the treatment[1][2].

Potential Benefits

While ATL001 is still being studied, researchers hope it may offer several potential benefits:

  • Personalized treatment targeting each patient’s specific cancer[1][2].
  • Potential to treat cancers that have not responded to other therapies[1][2].
  • Possible improvement in tumor size and overall survival[1][2].

Safety Considerations

As with any new treatment, there are potential risks and side effects. The clinical trials are carefully monitoring patients for:

  • Adverse events (side effects) related to ATL001 and other drugs used in the treatment process[1][2].
  • How well patients tolerate the treatment[1][2].
  • Any serious side effects that may occur[1][2].

It’s important to note that ATL001 is still an experimental treatment. More research is needed to fully understand its effectiveness and safety profile. Patients interested in this treatment should discuss it with their healthcare provider to determine if it might be appropriate for their specific situation.

Aspect Details
Treatment ATL001 (personalized T cell therapy)
Conditions studied Advanced non-small cell lung cancer (NSCLC), Metastatic or recurrent melanoma
Trial phase Phase I/IIa
Administration Intravenous infusion
Combination therapies Pembrolizumab (for NSCLC), Nivolumab (for melanoma)
Primary objective Assess safety and tolerability
Secondary objectives Evaluate clinical efficacy (tumor size changes, response rates, survival outcomes)
Key eligibility criteria Adults with advanced disease, prior treatment with PD-1/PD-L1 inhibitor, adequate organ function
Main exclusion criteria Untreated brain metastases, active autoimmune diseases, recent live vaccinations

FAQ

  • What is ATL001? ATL001 is a personalized therapy that uses a patient's own T cells, which are modified to target specific mutations found in their cancer cells. It's currently being tested for advanced non-small cell lung cancer and metastatic or recurrent melanoma.
  • How is ATL001 administered? ATL001 is administered as a dispersion for infusion, which means it's given intravenously (through a vein) to the patient.
  • Who is eligible for these clinical trials? Eligibility varies, but generally includes adult patients with advanced NSCLC or metastatic melanoma who have either progressed after standard treatments or are ineligible for standard therapies. Specific criteria include adequate organ function and performance status.
  • What are the main goals of these clinical trials? The primary goal is to assess the safety and tolerability of ATL001. Secondary goals include evaluating its clinical effectiveness, such as changes in tumor size, overall response rate, and survival outcomes.
  • Are there any side effects associated with ATL001? As with any clinical trial, potential side effects are being closely monitored. The trials are specifically tracking the frequency and severity of adverse events following tissue procurement, lymphodepletion, ATL001 administration, and other associated treatments.

Ongoing Clinical Trials on Atl001

  • Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain

Glossary

  • Non-small cell lung cancer (NSCLC): A type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers. It grows and spreads more slowly than small cell lung cancer.
  • Melanoma: A serious type of skin cancer that develops in the cells (melanocytes) that produce melanin, the pigment that gives your skin its color.
  • T cells: A type of white blood cell that is part of the immune system and develops from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function.
  • Pembrolizumab: An immunotherapy drug used in some cancer treatments. It works by helping the immune system recognize and attack cancer cells.
  • Nivolumab: Another immunotherapy drug similar to pembrolizumab, used in cancer treatment to help the immune system fight cancer cells.
  • Lymphodepletion: A process that temporarily reduces the number of lymphocytes (a type of white blood cell) in the body. This is often done before certain cancer treatments to improve their effectiveness.
  • RECIST: Response Evaluation Criteria In Solid Tumors. It's a standard way to measure how well a cancer patient responds to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/